共 19 条
- [1] Structure activity relationship study of N6-(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogs: Development of highly selective D3 dopamine receptor agonists and their pharmacological characterization ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
- [2] Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl) piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (12) : 5826 - 5840
- [3] Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (23) : 9179 - 9195
- [4] Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization (vol 55, pg 5826, 2012) JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (02) : 589 - 590
- [5] Development of (S)-N6-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6, 7-tetrahydrobenzo[d]-thiazole-2,6-diamine and Its Analogue as a D3 Receptor Preferring Agonist: Potent in Vivo Activity in Parkinson's Disease Animal Models JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (03) : 1023 - 1037
- [6] Structural Modifications of Neuroprotective Anti-Parkinsonian (-)-N6-(2-(4-(Biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): An Effort toward the Improvement of in Vivo Efficacy of the Parent Molecule JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (04) : 1557 - 1572
- [7] Interaction of D3 preferring agonist (−)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D2L, D2S, and D3 receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386 : 97 - 105
- [8] Interaction of D3 preferring agonist (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D2L, D2S, and D3 receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 (02) : 97 - 105
- [9] Structural modification of (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d] thiazole-2,6-diamine (D-264): An effort to improve the blood brain barrier crossing ability and multifunctional property in lead compounds for the treatment of Parkinson's disease ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
- [10] Further structure activity relationship (SAR) study of novel hybrid 7-{[2-(4-Phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol analogs focusing on modification of the N-aromatic moiety: Development of a highly potent and selective lead molecule for the D3 dopamine receptor ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 655 - 655